PreveCeutical crowned for its Innovative Pain Therapy Technology

Announcement

PreveCeutical Medical Inc. is excited to declare its authorisation, as the Australian Patent Office has awarded Australian Patent No. AU2020212659, headlined “A Cyclic Peptide”. This headline is based on the Company’s pain therapy program. This authorisation marks a valuable milestone in shielding and development of PreveCeutical’s exclusive technologies focused on identifying the unmet, neglected needs in pain management. With this authorisation, the company’s promising technologies will get a boost of confident expansion.

The pain management market will get a push to rely on and embed into the tech health with this patented right. The technology in the healthcare sector has always played a significant role, but the trademark gives confidence to the hospital and practitioners to rely on the same for the lives of the patients. This earned patent delivers the required protection to the Australian region for novel cyclized peptides that are counterparts of dynorphin, an endogenous opioid peptide.

These compounds are engineered to serve effective pain relief while simultaneously mitigating the negative effects commonly linked with traditional opioid therapies like tolerance and dependence. The discovery covers pharmaceutical methods and compositions execution for preventing and curing pain in subjects and bolsters the therapeutic capability of this technology. This authorisation is mutually owned by The University of Queensland and PreveCeutical Medical Inc. This mirrors the power of the collaborative definitive research partnership between the two respective organisations.

The patent serves exclusivity in the Australian region till January 2040, which will be bound to maintenance and build a part of a wide patent family with reciprocal applications left out in Canada, Europe and the United States. This universal smart strategy promises major help for its long-standing marketing objectives and a shield for PreveCeutical’s intellectual property portfolio.

PreveCeutical’s pain therapy program

The PreveCeutical’s pain therapy program aims to establish next-generation peptide-related analgesics that further focus on fighting the limitations of conventional opioids. By accelerating the cyclisation techniques and modern peptide engineering, these candidates are engineered to demonstrate receptor selectivity and improved stability, which might prominently enhance patient outcomes in dealing with chronic and acute pain.

PreveCeutical CEO, Stephen Van Deventer, said, “The grant of this authorisation is a noteworthy success for PreveCeutical and underlines our dedication to revolutionising the innovative solutions for pain management. This smart intellectual property powers our footprint in a global market searching safest options to opioids and contributes to our long-standing marketing strategy.”